Oct 20, 2016
Cynata’s MSC Technology Demonstrates Significant Efficacy in Preclinical Asthma Study
Cynata’s MSC Technology Demonstrates Significant Efficacy in Preclinical Asthma Study
An Australian stem cell company called Cynata Therapeutics Limited is in the process of developing a therapeutic stem cell platform technology that they called “Cymerus.” The idea for Cymerus originated at the University of Wisconsin-Madison, but Cymerus would generate a protocol by which clinical laboratories could produce very immature mesenchymal stem cells from induced pluripotent stem cells.…
View On WordPress